CD8A and allergic disease: Thus, we can only speculate how BX-795 may act on other cell types such as, e.g., CD8+ T cells, dendritic cells or type 2 innate lymphoid cells (ILCs), the latter representing recently discovered key players in the initial phase of allergic diseases (83).